NEWARK, Calif., June 18, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $30.50 per share pursuant to a registration statement filed with the Securities and Exchange Commission (SEC). All of the shares in the offering are to be sold by Revance. In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 600,000 shares from Revance. The offering is expected to close on June 24, 2014, subject to customary closing conditions.
Help employers find you! Check out all the jobs and post your resume.